Edition:
NIAID Funding News provides funding, policy, and other information to NIAID's extramural research community and Institute staff. Visit Stay Informed About Policy Changes and News for more opportunities to connect with us.
Changing Institutions? Steps to Take for a Grant to Go with You
If you are conducting human subjects research or research using vertebrate animals, you’ll need to begin the institutional review board or institutional animal care and use process, respectively, at the new institution.
When a Modular Budget Is Right for You
Request a budget sufficient to make your proposed project successful; reviewers will not respond well when faced with a budget that is clearly inflated or insufficient for the proposed work.
Don’t Derail Your Application: Avoid These Electronic Submission Errors
Submitting your application well in advance of its receipt date will allow you ample time to validate the upload and correct any content-related upload errors.
Tabulating NIAID’s R01 and R21 Application and Award Counts for FY 2024
Each year, we share the number of R01-equivalent and R21 applications that NIAID received in the previous fiscal year as well as the number of grants NIAID awarded.
Don’t Waste Your Time: Take an Extra Minute When Selecting NOFOs, Form Sets
We’ve now reached a stretch of time in which two form sets (i.e., FORMS-H and FORMS-I) and two versions of certain notices of funding opportunities (NOFOs) will be active simultaneously.
How to Use the World’s Largest Public Clinical Trials Registry as a Resource
While many researchers treat ClinicalTrials.gov only as a repository to submit required study information, it’s also worth thinking of it as an extensive online library.
Long COVID and the RECOVER-TLC Initiative
Long COVID’s broad and varied effects on diverse populations demand new clinical approaches and fewer restrictions to inclusion and access to achieve breakthrough results.
NIAID Sets Interim Paylines, Financial Management Plan for FY 2025
Remember, paylines are funding cutoff points for investigator-initiated grant applications based on score during peer review. Notably, we’ve already set interim paylines for every relevant award type.
Happenings from the September Meeting of NIAID’s Advisory Council
NIAID Director Dr. Jeanne Marrazzo shared remarks before NIAID's Advisory Council, as did Dr. Ted Piersen, Director of NIAID’s Vaccine Research Center.
What Is the NIAID Advisory Council and What Does It Do?
NIAID's Advisory Council is comprised of both experts in health and science, contributing technical expertise and an understanding of the needs of research communities of academia and industry, and lay members, who impart a perspective of people and communities affected by diseases in the NIAID research mission.
Explore NIAID Topics for Small Business Innovation Research Contract Solicitation
The annual NIH solicitation serves as a vehicle for offerors to propose research projects on a multitude of scientific topics from across NIH. Proposals are due October 18, 2024.
Small Business Research: Priority Funding Topics for 2025
NIH assembled a list of scientific priorities for small business awards that match the research interests of its institutes and centers, including NIAID.
Check Whether Your Research Is a Good Fit for ARPA-H
The Advanced Research Projects Agency for Health (ARPA-H) aims to advance high-potential, high-impact biomedical and health research that cannot be readily accomplished through traditional research or commercial activity.
Looking to the Future at the June Meeting of NIAID’s Advisory Council
NIAID Director Dr. Jeanne Marrazzo shared remarks before NIAID's Advisory Council, as did Dr. Steven Holland, Director of NIAID's Division of Intramural Research.
Explore Spending Estimates and Public Health Burden by Disease Category
NIAID often encourages researchers to use NIH RePORT tools—including Research, Condition, and Disease Categorization (RCDC)—to identify potential collaborators.
Bookmark NIH Webinars Page for Upcoming and Past Events on Funding Topics
For recently established policies, watching a webinar may prove an easier path to understanding NIH's new procedures than would reading policy announcements.
Learn About NIAID Career Opportunities and How to Apply
While many jobs at NIAID require expertise specific to our area of science, you'll notice that many position titles and functional roles are often similar across NIH’s many institutes and centers.
Explore the World of Research and Development Contract Solicitations
Contracts are government requirements for a product or service with specific goals, deliverables, and deadlines, and work done under a contract requires programmatic oversight by NIAID staff.
FORMS-I Transition: Setting Up Dominoes to Topple on January 25, 2025
NIH will transition to FORMS-I for application due dates on or after January 25, 2025, and also implement new policies and procedures that accompany the switch.
Some Applications Have Deadlines for Actions Before the Due Date
NIAID staff can identify issues that may cause your application to be withdrawn, not fare well in peer review, or have lowered potential for an award. The earlier you contact us, the earlier we can provide advice that you can use to improve your application.
Know How to Demonstrate Scientific Progress in Annual Reports
Your program officer will assess the progress, delays, and planned next steps you describe and compare that to your budget request and justification for approval.
Examining NIAID’s R01 and R21 Application and Award Counts for FY 2023
We share the number of R01-equivalent and R21 applications that NIAID received in the previous fiscal year as well as the number of grants NIAID awarded. To add context, we present the data alongside the same figures for the preceding 4 years.
New Leaders Take Center Stage at Advisory Council Meeting in January
This was the first meeting at which NIAID Director Dr. Jeanne Marrazzo shared remarks before NIAID's Advisory Council. It was also the first time that guest speaker Dr. Monica Bertagnolli, NIH Director, addressed our Council.
NIAID Uses Selective Pay, Bridge Awards to Complement Top-Scoring Applications
NIAID strives to always fund those applications that score best in peer review, but we also discern which applications outside the payline can help guard against scientific gaps emerging in our research portfolio.
Know Your Timeline to Award If All Goes According to Plan
Knowing when NIAID will begin funding your project is essential—it’s necessary for hiring support staff or arranging subcontracts or even timing a renewal application.
Don’t Be Fazed by Phased Awards
Submitted applications contain plans for two phases of research, including milestones that the applicant believes will justify continued support into the second phase.
NIH or NIAID? Know the Difference
NIH is made up of 27 institutes and centers, each with a specific research agenda, often focusing on particular diseases or body systems.
How NIAID Sets a Payline—A Conservative Approach in Light of Uncertainty
We can increase a payline and then fund applications from earlier in the fiscal year that are now within the payline, but we cannot decrease a payline and pull back funding from awards already made.Successful Sample Applications Demonstrate Good Grantsmanship
To observe how other applicants approach grantsmanship, examine the text sections of the successful example applications—particularly the Specific Aims and Research Plans.
Top Ten Things NIH RePORT and RePORTER Can Do for You
Use custom crafted queries to learn what active research projects represent the cutting edge of your field, find potential collaborators for future projects, and much more.
Taking a New Approach to Our Research Training Portfolio
NIAID is committed to improving the availability and effectiveness of our training, fellowship, and career development awards, to include increased support for certain research training activity codes.Opportunities and Resources
We aim to increase understanding of these mechanisms in order to identify candidate markers of disease progression as well as potential targets for immune-modulatory treatment to decrease TB and HBV risks in people living with HIV.
The cooperative research program will support centers that integrate clinical and translational research to conduct studies on mechanisms underlying the onset and progression of asthma and allergic diseases.
This notice of funding opportunity supports basic research on HIV-1 Env biology, and/or translational research that develops or optimizes biologics.
NIAID will support the development of safe and effective long-acting/sustained release technologies to help prevent and treat HIV and related co-infections such as tuberculosis, hepatitis B, and hepatitis C.
NIAID will support multidisciplinary, collaborative research programs focused on discovery to early development research to inform new approaches to prevent, diagnose, and treat antibiotic-resistant bacterial infections.
Propose a multidisciplinary research group that will implement phage therapeutic research by focusing on preclinical development and study pharmacokinetics and pharmacodynamics.
NIAID seeks to capitalize on the robust herpes simplex virus basic research field and to encourage more researchers to advance products into the development pipeline.
We seek milestone-driven, early-stage translational research focused on drug discovery and development of novel therapeutics against select fungal pathogens including Candida species that remain a clinical challenge.
Propose to discover and develop novel therapeutics directed at intracellular HIV targets and eliminate viral proteins by mechanisms like protein degradation, targeting of viral RNA through inhibiting RNA processing as well as degradation.
This opportunity is designed to support cohorts of the Pediatric HIV/AIDS Cohort Study—a streamlined and agile grant program that addresses developmental and clinical issues that affect individuals with HIV.
Projects should include meaningful engagement with implementing partners such as public health departments, healthcare organizations, and other service providers, as well as community members and people with lived experience.
Greater knowledge of the interactions and factors driving tuberculosis transmission would allow efficacious approaches for preventing transmission to be developed or improved and adapted for broad scale-up.
This opportunity encourages discovery and development of small molecule compounds with activity against viral targets that could be administered orally as monotherapy or in combination with other drugs to treat infections caused by viruses of pandemic potential.
Demonstrate innovative approaches to data reuse, explore strategies for leveraging data across data resources, and identify methods to ensure effective integration of data obtained through secondary analysis.
NIAID is interested in supporting research programs that focus on HIV and other health outcomes in women to inform and enable more targeted and effective HIV prevention and treatment.
Through a new initiative, we aim to fund hypothesis-driven research to investigate and improve the durability of immune responses to candidate vaccines for HIV prevention.
Apply to investigate the relationship between genetic variation in human leukocyte antigen and killer-cell immunoglobulin-like receptor region genomics and immune-mediated diseases.
NIAID will support studies that examine the impact of hormone therapy and antiretroviral drugs on treatment and prevention methods of HIV and other sexually transmitted infections.
Build a practical clinical research platform for rapidly and efficiently profiling participants’ intact, rebound-competent HIV reservoirs and their immunologic profiles.
NIAID will support basic research to elucidate mechanistic differences in susceptibility to chemicals of concern between pediatric and adult populations as well as applied research towards the discovery and early development of pediatric-safe medical countermeasures.
Each award’s principal investigator should be an established investigator capable of providing administrative and scientific leadership to the development and implementation of a career development program.
The notice of special interest (NOSI) encourages grant applications from Small Business Concerns to develop commercializable tools, resources, and approaches to capture the effects of climate change and the associated impacts of extreme weather events on human health.
Apply for research support to study basic mechanisms and biomarkers of trained immunity (i.e., innate immune memory), plus the functional implications of trained immunity.
The NIAID Clinical Trial Implementation Cooperative Agreement notice of funding opportunity (NOFO) is designed for high-risk trials. The NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement NOFO allows small business concerns to proposed investigator-initiated clinical trials.
NIAID aims to better understand the mechanisms by which bats regulate immune responses to clear infection and prevent or resolve excessive inflammation.
3D organotypic culture models offer improved modeling of tissue architecture, cell-cell interactions, and other microenvironmental aspects of tissues and organ systems.
NIAID seeks research projects to discover and develop compounds that promote targeted protein degradation of viral, bacterial, parasitic, or fungal pathogen components, as well as non-protein targets.
The program provides comprehensive quality assessment evaluations for virologic assays for HIV and other viral pathogens performed on samples collected from participants enrolled in NIAID-sponsored and collaborative multisite clinical studies.
Propose research studies to explore the mechanisms of action of combination adjuvants that have already been shown individually to be effective in enhancing or modulating immune responses when compared with an antigen alone.
This notice of funding opportunity seeks research to characterize the role of defective HIV in blood and tissue sites in people living with HIV on antiretroviral therapy.
NIAID aims to foster new and innovative scientific endeavors related to universal influenza vaccine research that advance the major research areas defined in our Strategic Plan for the Development of a Universal Influenza Vaccine.
While most of our understanding of Post-TB Lung Disease (PTLD) comes from long-term human cohorts, using animal models for PTLD development could help address difficult mechanistic questions when relying solely on human studies.
Gather preliminary data around the role of understudied proteins associated with rare diseases and characterize new targets for treatment of human disease among them.
Find support for early- to mid-stage research and development of extracorporeal systems that mimic human responses and test appropriate medical countermeasures to treat civilian populations.
Submit an application to help foster, stimulate, and expand research on HIV/AIDS, HIV/AIDS comorbidities and co-infections, HIV/AIDS-associated implementation science, and HIV/AIDS-associated data science.
This initiative funds federally recognized American Indian/Alaska Native (AI/AN) tribes, tribal colleges or universities, tribal health programs, or tribal organizations to support health-related research, research career enhancement, and research infrastructure enhancement activities.
NIAID will help support and advance a human organ and tissue resource to provide a wide variety of human tissues and organs, diseased and normal, young and aged, to investigators for laboratory studies depending on research needs.
Projects will focus on novel ideas in radiation research, specifically medical countermeasures, biodosimetry, or animal model development to diagnose, mitigate, or treat injuries sustained during a radiation mass casualty incident.
Apply for funding to research immunologic events in vertebrate hosts that occur at the bite site (skin) and systemically during and after feeding by hematophagous and ectoparasitic arthropods.
Investigate and advance the mechanistic understanding on how immune ontogeny and functionality in early life could be harnessed in the context of HIV vaccines and broadly neutralizing antibodies to protect against acquisition of HIV infection.
Conduct fundamental research to characterize the acute or long-term pathophysiological effects of toxic chemical exposure on the pulmonary, ocular, or neurological system.
This initiative aims to strengthen the research capacity of institutions in low- and middle-income countries to investigate methods for preventing, treating, and controlling infectious diseases that pose significant health risks.
Apply if you can conduct research to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in U.S. or global settings.
This opportunity will support milestone-driven projects focused on developing novel predictive models, assays, tools, or platforms aimed at gaining a better understanding of the rules and compound properties that govern the penetration and efflux of drug-like small molecules into Gram-negative bacterial pathogens.
The Immunobiology of Xenotransplantation Cooperative Research Program supports research in preclinical nonhuman primate and human decedent models of porcine pancreatic islet, kidney, heart, lung, or liver xenotransplantation.
The Centers for Research in Emerging Infectious Diseases Network works to expand knowledge of re-emerging and emerging infectious diseases around the globe.
Through this notice of funding opportunity, you can receive funding to pay for national, international, and regional conferences, meetings, and workshops. Keep in mind, this award is not meant to fund an individual’s travel to a conference; rather, the funds are provided to the conference organizer.
A new Center will perform activities to coordinate the modeling community through coordinating cores and conduct research projects to advance modeling across and between scales of infectious and immune-mediated disease.
The solicitation’s purpose is to support manufacturing of material to advance preclinical, nonclinical, and Phase I/II clinical studies (e.g., vaccines, other biologics, vaccine components, and reagents).
A new opportunity supports radiation research at all stages of development for identifying biomarkers of injury and developing assays or devices for the purpose of triage, including assessing absorbed dose or predicting health outcomes of acute or delayed injuries.
Focus on ethical, legal, and social implications (ELSI) research relevant to NIAID’s scientific mission: HIV/AIDS or its comorbidities; infectious diseases; organ transplantation; and ELSI of clinical trials and implementation science.
Conduct an innovative project to study the mechanisms and management of vaccine or antibiotic drug allergy, including research on allergic responses to anti-viral, anti-fungal, and anti-parasitic drugs.
Through courses for skills development and mentoring activities, NIAID strives to support current and future research investigators from diverse backgrounds.
This initiative will stimulate the optimization and evaluation of long-acting drug delivery systems formulations in suitable preclinical animal models at an earlier age of adult drug development.
The Mycobacterium tuberculosis (MTB) Quality Assessment Program will serve NIAID-sponsored and collaborating clinical trial networks and cohorts as well as individual grantees conducting research in and outside the United States.
The cohort study platform will collect and make publicly available high-quality risk factor, viral suppression, and other outcome data on HIV and associated comorbidities in middle-aged and older adults in the United States.
The initiative promotes discovery of novel, improved candidates for treating Botulinum Neurotoxin (BoNT) toxicity, as well as platforms for the intraneuronal delivery of antitoxins to reverse BoNT intoxication.
Advance our understanding of the impact of a host’s microbial experience on the development and function of host immunity and provide the data necessary to encourage broader use of the mouse models in immunologic and microbiologic research.
Propose research on the fundamental mechanisms of toxicity of highly toxic Chemicals of Concern but also on potential new targets to inform the development of medical countermeasures that would be effective during and after civilian mass exposure situations.
Research civilian chemical medical countermeasures and novel treatment strategies to combat serious morbidity and mortality resulting from high consequence public health chemical emergencies.
Active grant awardees can receive support for in-scope research to reduce health inequalities among women who are understudied, underrepresented, or underreported in biomedical research.
Recruit, mentor, and support students, postdoctoral scholars, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research.
Apply to organize a series of annual in-person scientific meetings, conferences, symposia, and workshops to advance innovations in therapeutic and chemical toxicology research.
Request support for basic and exploratory research projects that leverage recent scientific development to advance our understanding of Treponema pallidum bacterial pathogenesis.
Develop and validate use of Collaborative Cross mouse models to reproduce the impact of host genetic variations on human immune system responses, and screen and evaluate mouse lines for use in specific studies and disease models.
Apply for funding to conduct innovative basic, translational, and clinical research to identify and address epigenetic treatment strategies for achieving hepatitis B virus (HBV) cure in people living with HIV.
The Lasker Scholars program supports candidates in two phases: an initial phase within the NIH Intramural Research Program and a subsequent phase with extramural grant funding.
NIAID will establish a Coordination, Consultation, and Data Management Center and multiple Regional Consultation Hubs to support NIH's Ending the HIV Epidemic in the U.S. Initiative research portfolio.
Conduct product-focused research to advance controlled-release vaccine strategies shown to improve immune responses for HIV prevention, treatment, and cure, and also to develop simplified or single-shot vaccination formulations.
Research the causes and mechanisms of inborn errors of immunity, enable early detection and molecular diagnosis, and support strategies to treat and cure these disorders.
Apply to test and evaluate non-viral technologies capable of delivering RNA-based therapeutics into disease-relevant cells and tissues in vivo through a new notice of special interest.
Our Radiation and Nuclear Countermeasures Program seeks a contractor who can provide services and capabilities to maintain and expand a centralized dosimetry harmonization effort.
NIAID seeks applications from single institutions or consortia of institutions ready to generate, validate, and advance medical countermeasures against a select list of bacteria or fungi with known or emerging resistance to current therapies.
NIAID invites applications from actively-funded grant recipients to travel to NIAID laboratories for a short duration to perform research in partnership with a host intramural research investigator.
NIAID will fund research on late-stage engineering and preclinical development of innovative biological products that safely and specifically engage the immune system to kill HIV-infected cells.
Each center will create and provide access to interactive knowlegebases, innovative tools and software, and leading-edge expertise in bioinformatics.
NIAID's Division of Microbiology and Infectious Diseases will use this Broad Agency Announcement to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases.
Help ensure future effective global malaria control and elimination by focusing on “combination” vaccine concepts to improve efficacy, targeting one or more parasite antigens of the different life cycle stages of the parasites.
Predoctoral trainees should become capable of applying data science methods and technologies across infectious and immune-mediated diseases research domains.
Each consortium will advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research.
Apply if you can further the development of new products to prevent herpes simplex virus infection and improve the diagnosis and treatment of patients living with herpes.
NIAID will support integrated multi-project research programs applying emerging and improved technologies to develop innovative gene- or cell-based HIV cure approaches.
Propose a partnership of investigators and existing clinical study sites in tuberculosis (TB) endemic countries, to evaluate early-stage TB diagnostic tests, assays, and strategies.
NIH seeks research projects studying the ethical, legal, and social implications of human genetic or genomic research, including empirical qualitative and quantitative methods.
Apply to conduct mid-stage research developing candidate medical countermeasures (MCMs) already demonstrating efficacy to mitigate or treat radiation injuries.
Study the epidemiology of viral HIV suppression and determine study approaches or evidence-based digital treatment interventions to reduce HIV transmission in Mexico and South and Central America.
Apply to conduct research on disease and health conditions that predominantly affect women, present and progress differently in women, or are female-specific.
In The News
If you are applying to a parent Fellowship notice of funding opportunity for the April 8 or May 7, 2025 Standard Due Dates, you must use the FORMS-H application forms and instructions.
NIAID will remain funded at the level of fiscal year 2024 appropriations through March 14, 2025, when the current continuing resolution will expire.
The new NIH policy mandates the submission of author-accepted manuscripts to NIH's PubMed Central without a 12-month embargo period.
NIH’s Advisory Committee to the Director (ACD) provides recommendations on program development, resource allocation, NIH administrative regulation, and other aspects of NIH policy.
The newly structured candidate section will ask for four personal statements: 1) a statement of professional and fellowship goals, 2) a statement of fellowship qualifications, 3) a self-assessment, and 4) a statement of scientific perspective.
A new initiative will support efforts to independently replicate significant lines of research and validate novel technologies across different scientific research areas in preclinical, translational, and technology development studies.
Recipients of grants and cooperative agreements are now required to include in their Research Performance Progress Reports responses to several new questions that align with the Final NIH Policy for Data Management and Sharing.
Last week, NIH completed a major overhaul of its Grants & Funding website. You can watch a video tour for a summary of key changes to the site’s organization and resources.
As of October 1, 2024, NIH’s eRA system will no longer automatically generate and send just-in-time email notifications to applicants whose overall impact scores are below a designated level.
NIH seeks community feedback on several recommendations made by the Advisory Committee to the Director Working Group on Re-Envisioning NIH-Supported Postdoctoral Training.
To be eligible, you must be a doctoral-level clinician or researcher who’s committed to conducting NIH-qualified clinical research. If NIH approves your application, we will repay up to $50,000 each year toward your qualified educational debt.
The draft Public Access Policy builds upon NIH’s history of providing public access to scholarly publications resulting from the research it supports and proposes additional steps to accelerate access.
NIH’s Advisory Committee to the Director (ACD) provides recommendations on program development, resource allocation, NIH administrative regulation, and other aspects of NIH policy.
When you complete your next Research Performance Progress Report, you may encounter new questions that address the NIH Data Management and Sharing (DMS) Policy.
Answer a request for information on topics that NIH should consider when developing the next NIH-wide Strategic Plan for Sexual and Gender Minority Health Research.
NIH announced Ruth L. Kirschstein National Research Service Award (NRSA) stipend levels for awards made on or after October 1, 2023, which saw their largest year-over-year increase since fiscal year 2017.
NIAID now has an appropriation for fiscal year 2024, a key development as we determine how many awards the Institute can support in this fiscal year.
The volume of awards that NIH is already obligated to fund each year can amplify, limit, or delay changes in success rates following a change in the overall budget.
To be accepted within an application, your video must demonstrate devices or experimental data with a temporal element, i.e., a need to show how something functions or occurs over time, or demonstrate movement or change.
Join us in our annual appreciation of NIAID peer review and committee members, then learn how to volunteer for a peer review group yourself.
NIAID is now updating its Institute-wide Strategic Plan, and we invite feedback from the extramural research community on the research priorities and crosscutting themes that will drive our Strategic Plan.
Our online database serves as a central resource for country-specific clinical research requirements for regulatory and ethics approval, clinical trial lifecycle, sponsor responsibilities, informed consent, investigational products, and specimens.
NIH’s Advisory Committee to the Director (ACD) members provide recommendations on program development, resource allocation, NIH administrative regulation, and other aspects of NIH policy.
Establishing an NIH-wide strategic plan will help the new Office of Autoimmune Disease Research create opportunities for synergistic innovation and implement cross-cutting research.
Learn about those exceptional researchers whose projects are already funded through the NIAID New Innovators Awards program.
Use the Budget Data Comparisons table to compare the enacted funding levels for fiscal years 2022 and 2023 across multiple NIH institutes and centers, including NIAID.
We are starting fiscal year 2023 under a continuing resolution, which will run through December 16, 2022. Our budget officials are now calculating appropriate interim payline levels.
Paylines—either percentiles (R01s only) or overall impact score order—are the funding cutoff points for investigator-initiated applications.
Unsure How to Link Your ORCID iD and eRA Commons Account? Watch This Video; New NIH Policy Ensures Patient Access to Certain Licensed Products; NIH Implements New Funding Opportunity Goals Text
NIH Releases Midcourse Review of the NIH-Wide Strategic Plan; New Resources Webpage for Researchers with Disabilities; Bookmark a Pair of NIH Informational Pages
NIH invites feedback that will help shape the framework of the ensuing NIH Strategic Plan for Disability Health Research for Fiscal Years 2026 to 2030.
Increased Interim Paylines for Fellowship, Career Development Awards; NIH Develops Training Resources for Responsible Conduct of Research; Enhance Your Presentations with High-Quality Science and Biomedical Art Illustrations
Investigators will soon be required to use Science Experts Network Curriculum Vitae (SciENcv) to complete Common Forms and the NIH Biographical Sketch Supplement to produce digitally certified PDFs for their application submission.
Note an Addendum to NIAID’s Financial Management Plan for FY 2025; HHS ASPR Posts FAQs on DURC/PEPP Policy; New Scientific Integrity Policies Focus on Public Trust
Last Call to Answer the NIAID Funding News Survey; Register Now for Small Business Entrepreneurship Boot Camp; Double Dipping Could Lead to Payback; Instruction for Labs Working with Synthetic Nucleic Acids
To aid researchers planning such studies around the globe, NIAID maintains the ClinRegs database of country-specific, clinical research regulatory information for 23 countries.
Join NIH policy experts for a webinar covering essential updates and ways in which the latest changes in NIH policies, systems, and resources might impact your institution’s grants administration procedures.
Foreign organizations that expend $750,000 or more in federal awards during their fiscal year must conduct either a single audit, performed in accordance with the requirements outlined in 2 CFR 200 Subpart F, or a program-specific audit.
Beginning on May 25, 2025, NIH will require grant applicants and recipients to use Common Forms for Biographical Sketch and Current and Pending (Other) Support, rather than the NIH-specific format pages currently in use.
NIH and NIAID prioritize support for early-stage investigators as a strategy to sustainably strengthen a robust and diverse workforce.
A central goal of NIH policies is to ensure that the demographics of participants in our clinical research will inform clinical practice to benefit people who are affected by the disease or condition under study.
Through a new request for information (RFI), NIH seeks input about engaging the public throughout all stages of clinical research; not solely during recruitment or participation in clinical research and trials.
Provide feedback on a draft policy and accompanying draft license agreement language that incorporates patient access in the commercialization process for NIH-owned inventions.
FDA and NIH are requesting comments regarding the clinical research terms related to innovative clinical study designs, including studies using real-world data to generate real-world evidence.
We announced a medley of changes for our career development and institutional training awards meant to help us better foster future investigators and maintain a balanced research training portfolio.
NIAID shares sample applications to provide examples of good grantsmanship and successful approaches to presenting a Research Strategy and Specific Aims.
Parent R01, R03, R21 NOFOs Will Now Expire in January 2025; Consider a New Perspective on Writing with Narrative Structure for Grant Applications; Remember May 27 Deadline for Input on NIAID’s Next Strategic Plan
The Cumulative Investigator Rate is an NIH-wide person-based metric, calculated as the number of unique principal investigators (PIs) who were designated on a research project grant (RPG) award, divided by the number of unique PIs who were designated on an RPG application over a 5-year period.
NIAID’s TB Portals Program is a global collaboration of clinicians, researchers, and data scientists united in the mission to eradicate tuberculosis.
Each National Research Service Award fellow or trainee is eligible to receive $2,500 per budget period toward expenses for childcare provided by a licensed childcare provider.
If a recipient does not submit all required closeout reports within a year of the period of performance end date, NIH must unilaterally close the grant and report the recipient's failure to comply with the terms and conditions of award.
NIH's Data Management and Sharing (DMS) Policy requires sharing of all scientific data, defined as all data necessary to replicate research findings regardless of whether the data are used to support scientific papers.
U.S. institutions can submit investigator-initiated grant applications and, if selected for funding, the Research Council of Finland may fully fund the Finnish investigators.
Subawards Policy Changes Take Effect on January 1, 2024; NIH Is Currently Operating Under a Continuing Resolution; Podcast Episodes Discuss the Hidden Curriculum for Early-Career Researchers
Dr. Monica Bertagnolli Is the New NIH Director; Attend Webinar for DEIA Excellence Supplemental Awards; Prepare Now for Upcoming Opportunity on Systems Modeling; Register for Native American Health Research Webinar on January 25; Monthly Automated Reminders for Rejected Final FFRs
NIAID uses paylines as funding cutoff points for certain types of investigator-initiated grant applications. Last week, NIAID updated the interim paylines for research projects (R01), small grants (R03), and exploratory/developmental grants (R21).
Use New Versions of Parent Announcements; Comment on Use of Metadata to Increase Transparency of Research Results; Updated eRA Resource Aligns Training Tables with New FORMS-I Requirements; Stream NIAID's Advisory Council Meeting on January 27.
HHS Policy Also Caps Indirect Salaries Paid Using Award Funds; Small Business Recipients—Get Help to Hone Your Product Pitch; Read Summary of Recent Artificial Intelligence Use Cases at NIH
With Gratitude to Dr. Hugh Auchincloss, and a Welcome to Dr. Sarah Read; Newcomer to NIH Funding? Attend the NIH Grants Process Primer Webinar; OLAW Annual Reports Are Due on December 1; Loan Repayment Program Application Deadline Is November 21
Reminder of NIH Policy on Late Applications Caused by Weather Emergencies; Examine Data on Professional Degree Types in NIH’s Grant Portfolio; NIH Revises Its Definition of Sexual and Gender Minority Populations
A Reminder for Authorized Organization Representatives to Verify Grant Assignments; NIAID Continues Participation in Ecology and Evolution of Infectious Diseases Program; Refresh Your Knowledge of NIAID and NIH Data Sharing Policies; Award Challenge Offers Prizes for Data Reuse Projects
Attend NIH Webinars on Grant Closeout, Fellowship Application and Review; Stay Sharp on Best Practices for Genomic Data Sharing; A Reminder for Small Businesses Seeking Funding in Women’s Health Research; Subscribe to New Quarterly Newsletter from COSWD for Funding Insights
Now Available: New Career Development Sample Applications; Hurry with Submissions for NIH Entrepreneurship Bootcamp; Distinguish the Priority Areas of NIH’s Institutes, Centers, and Offices
Change in Prior Approval Requirements for SBIR/STTR Recipients to Add a Subaward; Funding for Meetings to Support Data Harmonization of Autoimmune Disease Research
NIAID Strives to End the Use of Stigmatizing Language; Contract Vendors Can Submit Inclusion Data Directly into HSS; Nominate a Researcher for 2024 SGM Research Awards Program
Temporary Exemption of H5 Avian Influenza Viruses from Select Agents Regulations; NIH Sets Expectations for Upholding the NIH-Lacks Family Agreement; Answer Request for Information on All of Us Research Program Data
New Government-Wide Policy for Dual Use Research of Concern and Pathogens with Enhanced Pandemic Potential in May 2025; NIAID Sets Final R01, R03, and R21 Paylines for FY 2024; NIH Increases Childcare Support for NRSA Fellows and Trainees
Share feedback on existing immunology resources, future needs of the research community, and potential future directions of data and knowledge management.
Senior investigators should concern themselves with the career trajectory of promising HIV researchers, and at NIAID we are exploring ways to maximize our resources to fund as many worthy candidates as possible.
Register for April 17 Webinar on Simplified Review Criteria; NIAID Receives an Appropriation for Fiscal Year 2024; NIH’s Office of Laboratory Animal Welfare Suggests Flexibilities
NIH invites community feedback on upcoming efforts to develop and implement a set of minimum core common data elements for NIH-funded clinical research and trials.
NIH’s Office of AIDS Research will use its next Strategic Plan as a basis for developing the NIH HIV research budget, outlining HIV research priorities, and conveying information about NIH HIV research priorities to the scientific community.
The direct salary for individuals under NIH grant and cooperative agreement awards cannot exceed “Executive Level II” of the Federal Executive pay scale. Effective January 1, 2024, the salary limitation for Executive Level II is $221,900.
NIAID Is Operating Under a Continuing Resolution; Bookmark Helpful NIH SEED Resources for Small Businesses; Prepare Now for Opportunity on Cell and Gene Therapies for HIV Cure; Watch Webinar to Hone Applications for DEIA Supplements
The initiative is designed for early-stage investigators who want to initiate a research project in an area different from their previous research focus or training experience, and therefore have not produced preliminary data.
Bookmark Updated Version of NIH Grants Policy Statement; Coming Soon: Reissued Parent NOFOs for Small Business Grant Applications; Review List of NIH Legislative Mandates for Fiscal Year 2024; Grants.gov Downtime Scheduled for this Weekend
Attend “NIH Grants Process: A Brief Walk-Through for Beginners” Event on May 15; Reminders for Small Business Concerns: TABA Supplements and Foreign Disclosures; Webinar to Discuss U54 Opportunity on Systems Modeling of Infection and Immunity
Attend Research Education Program Webinar on April 4, Apply by June 7; Public Access Policy Webpages Are on the Move; A Note on the Next NIH Grants Policy Statement Release
NIAID is hosting a virtual grant writing webinar series called “Debuting Your Research Career: How to Plan for and Write Your First (or Next) NIH Grant Application.” This monthly webinar series is free and open to pre- and post-doctoral fellows, clinician-scientists, and early-career investigators.
Simplified Review Criteria Will Receive a Soft Launch; Provide Input on HIV Research Priorities Before March 28, 2024; Attend Virtual Seminar on Opportunities for Early-Career Researchers; NIH Has a YouTube Channel for Grants Policy Discussions
Tune in for NIAID Advisory Council Meeting on January 30, 2024; Attend NIH Office of Extramural Research Webinar on Grants Policy Changes; eRA Commons ID Required for Senior/Key Personnel, Other Significant Contributors; Offer Feedback on the NIH Strategic Plan for Data Science
Attend Seminar on How Diversity Impacts Innovation in Team Science; New Visual Appearance Planned for Popular eRA Modules
Advice Corner
Whether cultivating partnerships across fields and institutions resonates with your research goals, or you decide to pursue a notice of funding opportunity that requires collaborators, we suggest several resources to develop those pursuits.
The letters of support should reflect the roles and commitment of collaborators on the project as well as the rate and price for contracted services, while also aligning with your application’s research strategy and budget.
Learn how to better navigate the NIH grants application and award process.
Submitting complete and timely Federal Financial Reports is an important step to ensure NIAID’s prompt review and consideration of any carryover requests.
If you know your application will go to a Center for Scientific Review study section, you can request assignment to the most appropriate one.
The Small Business Administration (SBA) sets caps for total costs on small business grant awards for all federal agencies, above which an agency must request SBA approval.
NIAID recently posted two R01 sample applications and one K08 sample application to serve as examples of outstanding grantsmanship and demonstrate a successful approach to presenting a research plan.
If you or your institution receives a notification alerting you that a change was made to your application status, pay attention to the grant application number referenced in the message.
How familiar are you with NIAID’s solicitation and contract vocabulary? Test your knowledge by taking our quiz and pay attention to the explanations for each answer.
NIH requires disclosure of other support, foreign components, and conflicts of interest so that staff can ensure funded projects do not receive duplicative support, research is conducted objectively, and sensitive data are kept confidential.
When NIH issues a correction or update to an NIH Guide notice, the original notice’s text may not change since NIH can correct some fields in the original notice but not others.
Investigators must include plans for sharing unique model organisms and related resources in their grant applications or contract proposals. Investigators unable to share model organisms or resources are required to state why sharing is not feasible.
NIAID caps R01 research project grant renewals at 20 percent above the direct costs of the last competing award period, less the costs of certain items like subawards’ facilities and adminsitrative costs.
As an applicant or a funded investigator, there's a good chance you'll need guidance on administrative or budget matters related to your grant or cooperative agreement.
An ancillary study is an independent research project that uses samples or data from a parent study to extend knowledge in scientific areas beyond the original scope of the parent study. It may qualify as a clinical study or a clinical trial.
Most notices of funding opportunities list the application due date, peer review date, Advisory Council round, and earliest project start date in the “Key Dates” section of Part 1. Overview Information.
If you identify a mistake or a missing form while examining your application in the viewing window, then your signing official should reject the application so that you can correct the error and submit a replacement application.
NIH uses notices of special interest (NOSIs) to invite applications on high-priority and high-opportunity areas of science. NOSIs are designed to reduce administrative burden on NIH staff and grant applicants alike.
NIH staff use award citations to evaluate the impact of grant funding on scientific progress over time. Similarly, peer reviewers rely on award citations to help assess award productivity.
A competing revision provides additional funding for activities that call for an expansion of your original scope of award, whereas administrative supplements fund activities that, while unforeseen when the application was being submitted, are still within the scope of the project.
NIH’s Office of Research Infrastructure Programs supports purchases of state-of-the-art, commercially available instruments on shared-use basis to enable or enhance conduct of cutting-edge research by NIH-funded investigators.
Try to incorporate new preliminary data, literature citations, letters of reference, and any other relevant updates that came about in the months between submissions.
NIH defines a clinical trial as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions on health-related biomedical or behavioral outcomes.
Any recipient of federal support and the information they submit to the government is subject to the Freedom of Information Act (FOIA).
Within eRA’s Prior Approval Module, a variety of templates exist to facilitate the most common request types: carryover, change of investigator, no-cost extension, big grants, and withdrawal.
If you are planning a delayed start to a human subjects study but wrongly mark it as a delayed onset study, your application will be missing important details which may negatively affect your score.
Even successful partnerships experience disagreements and disputes. To ensure those moments don’t derail your science, you need to have an established conflict resolution plan.
Any time you read an NIAID notice of funding opportunity, build a habit of checking whether there is an associated questions and answers page.
Know how to respond if you get the error message “Data Management and Sharing Costs can only be entered on one of the lines in Section F Other Direct Costs within the same budget period."